{"id":40872,"date":"2025-09-08T14:39:11","date_gmt":"2025-09-08T06:39:11","guid":{"rendered":"https:\/\/flcube.com\/?p=40872"},"modified":"2025-09-08T14:39:12","modified_gmt":"2025-09-08T06:39:12","slug":"quantumpharm-xtalpi-secures-phase-i-approval-for-pep08-a-next%e2%80%91generation-prmt5-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40872","title":{"rendered":"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor"},"content":{"rendered":"\n<p>Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2228:HKG\">HKG: 2228<\/a>) announced a pivotal clinical milestone for <strong>PEP08<\/strong>, a next\u2011generation protein arginine\u2011methyltransferase\u202f5 (PRMT5) inhibitor developed in partnership with PharmaEngine, Inc. The drug has received Phase\u202fI clinical\u2011trial approval for solid tumors from the Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA). XtalPi will also receive a milestone payment tied to this approval.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-advantage\">Scientific Advantage<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Second\u2011Generation Design<\/strong> \u2013 PEP08 incorporates a novel chemical scaffold that delivers superior potency and selectivity over earlier PRMT5 inhibitors.<\/li>\n\n\n\n<li><strong>MTA\u2011Cooperative Binding<\/strong> \u2013 The compound forms a stable ternary complex with PRMT5 and the methyl\u2011transferase\u2011associated protein (MTA), locking the inhibitor into place and enhancing target engagement.<\/li>\n\n\n\n<li><strong>Tumor\u2011Selective Cytotoxicity<\/strong> \u2013 By exploiting the loss of MTAP in certain cancers, PEP08 selectively kills MTAP\u2011deleted tumor cells while sparing normal tissue, potentially reducing off\u2011target toxicity.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fI Authorization<\/strong> \u2013 Approved by HREC, TGA, and TFDA, PEP08 is now cleared to commence dose\u2011escalation studies in patients with advanced solid tumors.<\/li>\n\n\n\n<li><strong>Milestone Payment<\/strong> \u2013 QuantumPharm will receive a pre\u2011agreed milestone payment, underscoring investor confidence and providing additional capital for ongoing development.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Phase\u202fI\/II Initiation<\/strong> \u2013 Begin patient enrollment in late 2025, focusing on lung, breast, and gastrointestinal solid tumors.<\/li>\n\n\n\n<li><strong>Biomarker\u2011Driven Cohorts<\/strong> \u2013 Utilize MTAP status as a companion diagnostic to enrich for responsive populations.<\/li>\n\n\n\n<li><strong>Phase\u202fIII Strategy<\/strong> \u2013 Pending favorable safety and pharmacodynamic data, plan a randomized, controlled study targeting high\u2011MTAP\u2011deletion malignancies.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge<\/strong> \u2013 PEP08\u2019s unique mechanism and tumor\u2011selective profile differentiate it from other PRMT5 candidates in the pipeline.<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong> \u2013 The PharmaEngine collaboration brings advanced formulation expertise, enhancing the drug\u2019s clinical potential.<\/li>\n\n\n\n<li><strong>Investor Sentiment<\/strong> \u2013 The milestone payment and regulatory approvals are likely to buoy QuantumPharm\u2019s valuation and attract additional capital for broader oncology pursuits.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-conclusion\">Conclusion<\/h3>\n\n\n\n<p>QuantumPharm\u2019s XtalPi division has secured a significant regulatory win for PEP08, positioning the drug as a promising first\u2011in\u2011class PRMT5 inhibitor in the fight against solid tumors. With a robust development plan and a clear therapeutic niche, PEP08 could become a cornerstone of precision oncology in the coming years.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40880,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,1112,4338,695,696],"class_list":["post-40872","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-2228","tag-pharmaengine","tag-quantumpharm","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for PEP08, a next\u2011generation protein arginine\u2011methyltransferase\u202f5 (PRMT5) inhibitor developed in partnership with PharmaEngine, Inc. The drug has received Phase\u202fI clinical\u2011trial approval for solid tumors from the Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA). XtalPi will also receive a milestone payment tied to this approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40872\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for PEP08, a next\u2011generation protein arginine\u2011methyltransferase\u202f5 (PRMT5) inhibitor developed in partnership with PharmaEngine, Inc. The drug has received Phase\u202fI clinical\u2011trial approval for solid tumors from the Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA). XtalPi will also receive a milestone payment tied to this approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40872\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-08T06:39:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-08T06:39:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor\",\"datePublished\":\"2025-09-08T06:39:11+00:00\",\"dateModified\":\"2025-09-08T06:39:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872\"},\"wordCount\":377,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0805.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2228\",\"PharmaEngine\",\"QuantumPharm\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40872#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40872\",\"name\":\"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0805.webp\",\"datePublished\":\"2025-09-08T06:39:11+00:00\",\"dateModified\":\"2025-09-08T06:39:12+00:00\",\"description\":\"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for PEP08, a next\u2011generation protein arginine\u2011methyltransferase\u202f5 (PRMT5) inhibitor developed in partnership with PharmaEngine, Inc. The drug has received Phase\u202fI clinical\u2011trial approval for solid tumors from the Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA). XtalPi will also receive a milestone payment tied to this approval.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40872\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0805.webp\",\"width\":1080,\"height\":608,\"caption\":\"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40872#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for PEP08, a next\u2011generation protein arginine\u2011methyltransferase\u202f5 (PRMT5) inhibitor developed in partnership with PharmaEngine, Inc. The drug has received Phase\u202fI clinical\u2011trial approval for solid tumors from the Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA). XtalPi will also receive a milestone payment tied to this approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40872","og_locale":"en_US","og_type":"article","og_title":"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor","og_description":"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for PEP08, a next\u2011generation protein arginine\u2011methyltransferase\u202f5 (PRMT5) inhibitor developed in partnership with PharmaEngine, Inc. The drug has received Phase\u202fI clinical\u2011trial approval for solid tumors from the Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA). XtalPi will also receive a milestone payment tied to this approval.","og_url":"https:\/\/flcube.com\/?p=40872","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-08T06:39:11+00:00","article_modified_time":"2025-09-08T06:39:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40872#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40872"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor","datePublished":"2025-09-08T06:39:11+00:00","dateModified":"2025-09-08T06:39:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40872"},"wordCount":377,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40872#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0805.webp","keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 2228","PharmaEngine","QuantumPharm","Xtalpi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40872#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40872","url":"https:\/\/flcube.com\/?p=40872","name":"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40872#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40872#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0805.webp","datePublished":"2025-09-08T06:39:11+00:00","dateModified":"2025-09-08T06:39:12+00:00","description":"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for PEP08, a next\u2011generation protein arginine\u2011methyltransferase\u202f5 (PRMT5) inhibitor developed in partnership with PharmaEngine, Inc. The drug has received Phase\u202fI clinical\u2011trial approval for solid tumors from the Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA). XtalPi will also receive a milestone payment tied to this approval.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40872#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40872"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40872#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0805.webp","width":1080,"height":608,"caption":"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40872#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"QuantumPharm XtalPi Secures Phase\u202fI Approval for PEP08, a Next\u2011Generation PRMT5 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40872"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40872\/revisions"}],"predecessor-version":[{"id":40881,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40872\/revisions\/40881"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40880"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}